Antiretroviral Therapy: Pharmacology Chapter

Introduction/Overview

Antiretroviral therapy (ART) represents the cornerstone of contemporary HIV management, transforming a once fatal infection into a chronic, manageable disease. ART employs a combination of drugs that target distinct stages of the viral life cycle, thereby reducing viral replication, restoring immune competence, and preventing disease progression. The clinical relevance of ART extends beyond virologic suppression; it also mitigates opportunistic infections, malignancies, and non‑communicable comorbidities associated with HIV. Consequently, a thorough understanding of antiretroviral pharmacology is essential for clinicians and pharmacists involved in the multidisciplinary care of people living with HIV.

Learning objectives

• Identify the major classes of antiretroviral drugs and their chemical classifications.
• Explain the pharmacodynamic mechanisms that underlie viral inhibition for each drug class.
• Describe the pharmacokinetic profiles, including absorption, distribution, metabolism, and excretion, of representative antiretrovirals.
• Recognize approved indications, off‑label uses, and clinical considerations that influence regimen selection.
• Evaluate adverse effect profiles, drug interactions, and special patient populations to optimize therapeutic outcomes.

Classification

Drug Classes and Categories

The antiretroviral armamentarium is categorized into six principal pharmacologic classes, each targeting a distinct step of the HIV life cycle:

• Reverse Transcriptase Inhibitors (RTIs) – subdivided into nucleoside/nucleotide RTIs (NRTIs/NtRTIs) and non‑nucleoside RTIs (NNRTIs).
• Protease Inhibitors (PIs) – inhibit the HIV protease enzyme, essential for viral maturation.
• Integrase Strand Transfer Inhibitors (INSTIs) – block integration of viral DNA into the host genome.
• Entry/Attachment Inhibitors – include fusion inhibitors and CCR5 antagonists that prevent virus-cell membrane fusion.
• Phosphonate Analogs – e.g., tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), acting as NRTIs with unique pharmacokinetic properties.
• Pharmacologic Adjuncts – agents such as ritonavir or cobicistat that boost PI activity by inhibiting CYP3A4.

Chemical Classification

From a chemical standpoint, antiretrovirals are grouped according to structural motifs:

• Nucleoside analogs (e.g., zidovudine, lamivudine) structurally resemble natural nucleosides, modified to incorporate phosphonate or methylene groups.
• Nucleotide analogs (e.g., tenofovir, abacavir) possess a phosphonate or phosphates moiety directly attached to the base.
• Non‑nucleoside analogs (e.g., efavirenz, nevirapine) feature aromatic rings that bind to an allosteric pocket on reverse transcriptase.
• Protease inhibitors (e.g., lopinavir, atazanavir) are peptidomimetics with hydrophobic side chains designed to occupy the enzyme’s active site.
• Integrase inhibitors (e.g., raltegravir, dolutegravir) contain a diketo acid core that chelates divalent metal ions in the integrase active site.
• Fusion inhibitors (e.g., enfuvirtide) are linear peptides that interfere with the conformational change required for membrane fusion.

Mechanism of Action

Reverse Transcriptase Inhibitors

Nucleoside/Nucleotide RTIs

These agents act as chain terminators once phosphorylated intracellularly to the active triphosphate form. They compete with natural deoxynucleoside triphosphates for incorporation into the nascent viral DNA strand. Upon incorporation, the absence of a 3′‑hydroxyl group prevents further elongation, effectively terminating DNA synthesis. For example, zidovudine triphosphate binds to the reverse transcriptase active site and prevents addition of deoxyguanosine monophosphate.

Non‑nucleoside RTIs

NNRTIs bind to a hydrophobic pocket adjacent to the reverse transcriptase active site, inducing a conformational change that reduces enzymatic activity. This allosteric inhibition is reversible and does not require phosphorylation. Efavirenz, for instance, binds tightly to the NNRTI pocket, resulting in a decrease in polymerase activity without competing with natural nucleotides.

Protease Inhibitors

PIs mimic the transition state of the peptide substrate and occupy the catalytic aspartyl protease active site. By preventing the cleavage of Gag and Gag‑Pol polyproteins, they block the maturation of viral particles, yielding non‑infectious virions. The peptidomimetic structure of lopinavir, combined with a bulky hydrophobic side chain, confers high affinity for the protease pocket.

Integrase Strand Transfer Inhibitors

INSTIs chelate the divalent metal ions (Mg²⁺/Mn²⁺) at the integrase active site, thereby preventing the strand transfer step of viral DNA integration into host chromatin. The diketo acid motif of raltegravir coordinates these metals, blocking the nucleophilic attack on the 3′‑OH of the viral DNA.

Entry/Attachment Inhibitors

Fusion Inhibitors

Enfuvirtide binds to the gp41 transmembrane glycoprotein, inhibiting the conformational changes required for the fusion of viral and cellular membranes. This blockade prevents the entry of the viral capsid into the host cytoplasm.

CCR5 Antagonists

Mosunetuzumab and maraviroc competitively inhibit the CCR5 chemokine receptor on CD4+ T cells, thereby obstructing co‑receptor binding of the viral envelope protein gp120. This blocks the fusion step in a co-receptor–specific manner.

Phosphonate Analogs

Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of tenofovir, a nucleotide analog. Once intracellularly converted to tenofovir diphosphate, they act as NRTIs, incorporating into viral DNA and terminating chain elongation. Their distinct prodrug chemistry influences tissue distribution and toxicity profiles.

Pharmacokinetics

Absorption

Oral bioavailability varies widely among antiretrovirals. For example, ritonavir exhibits high oral absorption but is highly susceptible to first‑pass metabolism, necessitating pharmacokinetic boosting. Tenofovir disoproxil fumarate demonstrates moderate oral absorption (~25 %), whereas tenofovir alafenamide achieves improved cellular uptake due to its stability in plasma and efficient conversion within target cells.

Distribution

Volume of distribution (V_z) is influenced by lipophilicity and plasma protein binding. Highly lipophilic PIs such as atazanavir have large V_z values (≈ 500 L), enabling penetration into sanctuary sites like the central nervous system. Conversely, hydrophilic NRTIs such as abacavir exhibit limited tissue distribution (V_z ≈ 20 L). Plasma protein binding ranges from 3 % for tenofovir to > 90 % for lopinavir, affecting free drug concentration and drug interactions.

Metabolism

Metabolic pathways are heterogeneous. NNRTIs such as efavirenz undergo extensive hepatic CYP2B6 oxidation, producing active and inactive metabolites. PIs are primarily metabolized by CYP3A4, with concomitant inhibition by ritonavir or cobicistat to prolong systemic exposure. INSTIs are metabolized by uridine diphosphate glucuronosyltransferase (UGT1A1) and, to a lesser extent, CYP3A4. Tenofovir is not extensively metabolized, reducing the risk of hepatic enzyme induction.

Excretion

Renal excretion dominates for most NRTIs and INSTIs. Tenofovir is eliminated via glomerular filtration and active tubular secretion; renal impairment necessitates dose adjustment. Protease inhibitors are largely eliminated hepatically, with biliary excretion contributing to the final disposition. The elimination half‑life (t_1/2) ranges from 1–2 h for efavirenz to > 12 h for atazanavir, influencing dosing frequency.

Half‑Life and Dosing Considerations

Steady‑state concentrations are typically achieved after 3–5 half‑lives. Regimen simplification often favors once‑daily dosing to enhance adherence. However, drugs with narrow therapeutic windows, such as lopinavir/ritonavir, may require twice‑daily administration. The pharmacokinetic properties of each agent inform selection in special populations, including those with hepatic or renal dysfunction.

Therapeutic Uses/Clinical Applications

Approved Indications

All antiretrovirals are licensed for the treatment of HIV‑1 infection, intended to be used in combination regimens to minimize resistance development. Current first‑line regimens typically comprise two NRTIs plus a third agent from an NNRTI, PI, or INSTI class. The choice of regimen depends on efficacy, resistance profile, tolerability, and patient comorbidities.

Off‑Label Uses

In certain clinical scenarios, antiretrovirals are employed off‑label. For example, maraviroc has been utilized in the management of HIV‑associated pulmonary hypertension due to its vasodilatory properties. Additionally, the antiretroviral drug dolutegravir has been explored as a potential therapeutic agent in hepatitis B virus infection due to its cross‑reactivity against HBV polymerase. Off‑label use is generally restricted to evidence‑based indications and requires careful monitoring.

Regimen Optimization

Regimen selection is guided by resistance testing, viral load, CD4 count, and patient preferences. Dual therapy regimens, such as dolutegravir plus lamivudine, have shown non‑inferiority to triple therapy in certain patient populations, offering reduced drug exposure and potential cost savings. However, dual therapy remains reserved for patients with documented virologic suppression and low resistance risk.

Adverse Effects

Common Side Effects

• Gastrointestinal disturbances – nausea, vomiting, diarrhea, more frequent with ritonavir‑boosted PIs.
• Central nervous system effects – headache, insomnia, mood changes, particularly with efavirenz.
• Hepatotoxicity – elevated transaminases, primarily associated with PIs and certain NNRTIs.
• Metabolic complications – dyslipidemia, insulin resistance, lipodystrophy, common with older protease inhibitors.
• Renal toxicity – proximal tubular dysfunction and Fanconi syndrome with tenofovir disoproxil fumarate, mitigated with tenofovir alafenamide.

Serious or Rare Adverse Reactions

• Cardiac arrhythmias – QTc prolongation with certain PIs (e.g., atazanavir) and NNRTIs.
• Severe skin reactions – Stevens–Johnson syndrome with abacavir in HLA‑B*5701 carriers.
• Hypersensitivity reactions – particularly with efavirenz and nevirapine, presenting with rash and hepatotoxicity.
• Hepatic steatosis – associated with some PIs, especially when combined with statins.

Black Box Warnings

Several antiretrovirals carry black box warnings. Efavirenz: risk of hepatotoxicity and neuropsychiatric adverse events. Tenofovir disoproxil fumarate: risk of renal failure and bone mineral density loss. These warnings necessitate baseline assessment, periodic monitoring, and patient education to mitigate potential harm.

Drug Interactions

Major Drug-Drug Interactions

Antiretrovirals are notorious for interactions mediated by cytochrome P450 enzymes and transport proteins.

• CYP3A4 Induction/Inhibition – PIs such as ritonavir inhibit CYP3A4, increasing plasma concentrations of co‑administered drugs (e.g., warfarin, statins). Conversely, rifampin induces CYP3A4, reducing PI levels.
• Transporter Modulation – Protease inhibitors inhibit P‑glycoprotein and breast cancer resistance protein, affecting drugs like digoxin and methotrexate.
• Phosphodiesterase Inhibitors – Interactions with sildenafil and tadalafil may increase the risk of hypotension when combined with certain PIs.

Contraindications

Contraindications include severe hepatic impairment for NNRTIs and certain PIs, and renal impairment for NRTIs such as tenofovir disoproxil fumarate. Co‑administration with strong CYP3A4 inducers (e.g., carbamazepine) is contraindicated with ritonavir‑boosted regimens due to loss of therapeutic drug levels.

Special Considerations

Pregnancy and Lactation

Most antiretrovirals are classified as pregnancy category B or C. Tenofovir alafenamide and dolutegravir have favorable safety profiles in pregnancy. However, efavirenz’s teratogenic potential warrants caution during the first trimester. Breastfeeding is generally permitted with most agents, but certain PIs may pose risks; monitoring infant drug levels is advisable.

Pediatric and Geriatric Considerations

In pediatrics, dose adjustments based on weight and maturation of metabolic pathways are essential. For adolescents, adherence support is critical to prevent resistance. In geriatrics, polypharmacy increases the risk of interactions; dose reductions and therapeutic drug monitoring may be necessary.

Renal and Hepatic Impairment

Renal dosing adjustments are mandatory for NRTIs with significant renal clearance, particularly tenofovir disoproxil fumarate. Hepatic impairment necessitates caution with PIs and NNRTIs, which rely on hepatic metabolism. Pharmacokinetic modeling can guide individualized dosing in these populations.

Summary/Key Points

• Antiretroviral therapy employs multi‑class regimens to inhibit distinct stages of HIV replication.
• Pharmacokinetic variability among agents necessitates individualized dosing, especially in organ dysfunction.
• Drug interactions are frequent due to CYP3A4 and transporter involvement; vigilance is required to avoid therapeutic failure or toxicity.
• Adverse effect profiles vary by class, with particular attention to neuropsychiatric, hepatotoxic, and metabolic complications.
• Special populations—pregnant women, children, elderly, and patients with renal/hepatic impairment—require tailored regimens and rigorous monitoring.

In sum, a comprehensive grasp of antiretroviral pharmacology is indispensable for optimizing treatment outcomes, preventing resistance, and ensuring patient safety. Continued research and pharmacovigilance will further refine therapeutic strategies in the evolving landscape of HIV care.

References

1. Chabner BA, Longo DL. Cancer Chemotherapy, Immunotherapy and Biotherapy: Principles and Practice. 6th ed. Philadelphia: Wolters Kluwer; 2019.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.